GSK reports Q3 revenue up 5.7% and strong sales growth in HIV and cancer drugs.
GSK plc reported a 5.7% quarter-on-quarter revenue increase to $11.81 billion in Q3, beating analyst expectations. Key drivers included Cabenuva, its long-acting HIV treatment, which saw sales rise 35.2% year-over-year to $641 million, and Jemperli, ...
